Retinal Edema Market Expected to Witness Significant Growth Through 2032, Driven by Recent FDA Approvals and a Robust Clinical Pipeline | DelveInsight

The retinal edema market is witnessing significant growth, primarily fueled by the increasing prevalence of conditions associated with retinal edema, particularly diabetic macular edema, and a robust pipeline of innovative therapies by pharmaceutical giants, including Regeneron, Genentech/Roche, Opthea, Novartis, and Kodiak Sciences, among others.
DelveInsight's "Retinal Edema - Market Insight, Epidemiology And Market Forecast - 2032 [https://www.delveinsight.com/report-store/retinal-edema-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of the retinal edema treatment market, historical and forecasted epidemiology, and market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The report further assesses current treatment practices, emerging drugs, and retinal edema market drivers, providing a comprehensive overview of the factors influencing this rapidly evolving therapeutic landscape.

The retinal edema treatment market is experiencing strong growth across the 7MM, driven by rising cases of diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion. Furthermore, the US holds the largest retinal edema market share, mainly due to a large patient pool, high adoption of advanced therapies, and ongoing research and development activities, which collectively drive greater demand and higher spending on treatment.

Download the Retinal Edema Market Forecast Report to understand which factors are driving the Retinal Edema market @ Retinal Edema Market Trends [https://www.delveinsight.com/sample-request/retinal-edema-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Retinal edema epidemiological studies indicate an increasing prevalence in all the major markets, mainly due to rising rates of diabetes, aging populations, and associated conditions like diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion. Additionally, diabetic macular edema represents one of the most prevalent forms of retinal edema. According to DelveInsight's research, more than 5% of people with diabetes globally have diabetic macular edema, with prevalence rates varying across regions. Among patients with type 1 diabetes, diabetic macular edema prevalence ranges between 4.2% and 8%, while in patients with type 2 diabetes, prevalence ranges from 1.5% to 13%.

Discover evolving trends in the Retinal Edema patient pool forecasts @ Retinal Edema Epidemiological Analysis [https://www.delveinsight.com/sample-request/retinal-edema-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The current retinal edema treatment landscape is dominated by anti-VEGF therapies, which effectively reduce fluid buildup and improve vision. Key drugs include EYLEA HD (aflibercept) from Regeneron Pharmaceuticals (NASDAQ: REGN) and Bayer (ETR: BAYN), offering extended dosing intervals. VABYSMO (faricimab-svoa), developed by Genentech, represents a groundbreaking advancement as the first and only FDA-approved injectable eye medicine for both wet AMD and DME. Biosimilars like BYOOVIZ (Samsung Bioepis) and YESAFILI (Biocon Biologics) provide more cost-effective options with similar efficacy. Other notable companies in the field are Novartis, Genentech, and AbbVie, all contributing to ongoing innovation, including long-acting drug delivery systems and emerging oral therapies.

According to DelveInsight's pipeline analysis of retinal edema treatments, several biopharmaceutical companies, including Roche, Genentech, Kodiak Sciences, Outlook Therapeutics, Taiwan Liposome Company, and Ocuphire, are making significant progress in developing advanced therapies that could transform care for this condition.

Kodiak Sciences is advancing tarcocimab tedromer (KSI-301), which is engineered for extended durability in treating retinal vein occlusion and diabetic macular edema (DME). They are also working on KSI-101, which targets macular edema caused by inflammation and DME. Both treatments are currently in late-stage clinical trials.

Outlook Therapeutics is progressing with LYTENAVA (ONS-5010), a novel ophthalmic formulation of bevacizumab specifically designed for retinal diseases. Meanwhile, the Taiwan Liposome Company is developing TLC399 (ProDex), a long-acting injectable form of dexamethasone that uses a proprietary sustained-release delivery platform to treat macular edema.

In addition, oral therapies are emerging in this field, including APX3330 by Ocuphire, a Ref-1 inhibitor currently in development for diabetic retinopathy.

The report also offers a thorough analysis of recent developments in the retinal edema therapeutic landscape and discusses their implications for the competitive environment surrounding this condition.

In early 2025, several important FDA approvals and clinical trial updates have influenced the retinal edema treatment landscape. In February 2025, the FDA approved Roche's Susvimo (ranibizumab injection) for diabetic macular edema. This marked the introduction of the first continuous delivery treatment for diabetic macular edema, significantly reducing the need for frequent eye injections. Additionally, in March 2025, the FDA approved ENCELTO (revakinagene taroretcel-lwey), developed by Neurotech Pharmaceuticals, as the first treatment for Macular Telangiectasia type 2, utilizing an innovative encapsulated cell therapy platform.

New clinical trials are also in progress, including studies of a higher-dose aflibercept by Bayer for treating macular edema secondary to retinal vein occlusion, and Unity Biotechnology's Phase III trial of foselutoclax for diabetic macular edema.

Discover evolving trends in the Retinal Edema treatment landscape @ Retinal Edema Recent Developments [https://www.delveinsight.com/sample-request/retinal-edema-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Despite these advancements, there are several retinal edema market challenges. In April 2025, the FDA delivered a complete response letter for longer dosage intervals (24 weeks) in aflibercept for DME and wet AMD, indicating regulatory hurdles for extended treatment protocols. Additionally, inconsistencies in diagnostic approaches and limited access to specialized eye care remain barriers to optimal patient management across different regions.

Looking ahead, the retinal edema market is poised for continued growth driven by several factors, including the integration of AI in imaging diagnostics and personalized treatment approaches based on molecular profiling. As research continues to uncover the complex pathophysiology of retinal edema and associated conditions, the market is expected to expand substantially, offering more tailored treatment options and improved outcomes for patients suffering from this vision-threatening condition.

Table of Contents

1. Key Insights

2. Executive Summary of Retinal Edema

3. Retinal Edema Competitive Intelligence

4. Retinal Edema: Market Overview at a Glance

5. Retinal Edema: Disease Background and Overview

6. Patient Journey

7. Retinal Edema Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Retinal Edema Unmet Needs

10. Key Endpoints of Retinal Edema Treatment

11. Retinal Edema Marketed Products

12. Retinal Edema Emerging Therapies

13. Retinal Edema: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Retinal Edema

17. KOL Views

18. Retinal Edema Market Drivers

19. Retinal Edema Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports

Retinal Edema Pipeline Insight [https://www.delveinsight.com/sample-request/retinal-edema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Retinal Edema Pipeline Insight provides comprehensive insights about the Retinal Edema pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Retinal Edema companies, including Roche, Novartis, Bayer, Regeneron, AbbVie, Sanofi, Genentech, and Iveric Bio, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=retinal-edema-market-expected-to-witness-significant-growth-through-2032-driven-by-recent-fda-approvals-and-a-robust-clinical-pipeline-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.